Fortis Healthcare Ltd. (FORTIS) AI Stock Analysis

• Market Cap: ₹610.50B
• Dividend Yield: 0.11%
• Average Volume (3M): 66.29K
• Price to Earnings (P/E): 86.1
• Beta (1Y): 1.10
• Revenue Growth: 15.33%
• EPS Growth: 54.62%
• Country: IN
• Employees: 12,088
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Care Facilities
• EPS (TTM): 3.18
• Shares Outstanding: 754,958,100
• 10 Day Avg. Volume: 118,360
• 30 Day Avg. Volume: 66,292
• PEG Ratio: 2.28
• Price to Book (P/B): 5.83
• Price to Sales (P/S): 6.67
• P/FCF Ratio: 90.06
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,044.00
• Price Target Upside: 14.10% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): 14.27
• Revenue Forecast (FY): ₹91.75B

• Rating: 61 Neutral
• Price Target: ₹865.00 ▼(-5.46% Downside)
• Action: Reiterated Date: 11/15/25
• Date: Action: Reiterated 11/15/25

Fortis Healthcare Ltd. has a strong financial foundation, which is the most significant factor in its overall score. However, technical analysis indicates bearish momentum, and the high P/E ratio suggests overvaluation, both of which weigh down the overall score. The absence of earnings call data and corporate events means these factors do not influence the score.

Positive Factors

Consistent Revenue Growth

Sustained ~16% revenue growth reflects expanding patient volumes and service uptake across the hospital network. Over a 2–6 month horizon this trend underpins predictable top-line expansion, supports scale economics, and provides a base for reinvestment into capacity and specialties.

Improving Profitability and Margins

Gross margins averaging above 40% and a shift to positive net margins indicate durable cost control and improved case mix. These margin gains suggest the company can sustain operating leverage, convert revenue into earnings, and better fund operations and investment without reliance on transient items.

Strong Cash Generation

Meaningful growth in free cash flow and strong operating cash flow relative to net income show reliable cash conversion. Over months this supports debt servicing, targeted capex, and working capital needs, increasing financial flexibility and enabling measured network expansion.

Negative Factors

Outstanding Debt Level

Although debt-to-equity is improving, the absolute debt stock remains noteworthy. Servicing and refinancing obligations can constrain capital allocation, limit aggressive expansion or M&A, and increase vulnerability to interest rate moves, creating a persistent balance-sheet risk.

Capital Expenditure Volatility

Variable capex patterns produce uneven investing cash flows and can make free cash flow less predictable. This volatility complicates long-term planning for new facilities or upgrades, may force trade-offs between maintenance and growth, and raises execution risk over coming months.

Operational Sensitivity to Volume & Payer Mix

Hospital economics rely on occupancy, complex case mix, ARPOB and clinician availability. These structural dependencies mean revenue and margins can swing with patient volumes, reimbursement changes or staffing constraints, posing a persistent operational risk to near-term profitability.

Fortis Healthcare Ltd. Business Overview & Revenue Model

Company Description

Fortis Healthcare Limited, an integrated healthcare delivery service provider, offers secondary, tertiary, and quaternary care in India, the United Arab Emirates, Sri Lanka, and internationally. Its healthcare verticals comprise hospitals, diagnostics, and day care specialty facilities. The company offers services in the areas of cardiac science, cosmetology, dental science, dermatology, diabetes/endocrinology, emergency medicine, ENT, foetal medicine, gastroenterology and hepatology science, general surgery, haematology, infertility medicine, internal medicine, mental health and behavioral science, nephrology, neuro surgery, neurointerventional radiology, neurology, obstetrics and gynaecology, oncology, ophthalmology, orthopedics, pediatrics, physiotherapy and rehabilitation, plastic and reconstructive surgery, pulmonology, radiology, rheumatology, thoracic surgery, transplantation medicine, urology, and other support specialties. As of March 31, 2022, it operated a network of 26 hospitals with approximately 4,300 operational beds. The company also operates approximately 426 diagnostics centers and laboratories; and 2,550 collection centers. The company was incorporated in 1996 and is based in Gurugram, India.

How the Company Makes Money

Fortis Healthcare primarily generates revenue from providing healthcare services through its hospital network. Key revenue streams typically include (1) inpatient services (room charges, nursing, ICU, inpatient procedures and surgeries), (2) outpatient services (doctor consultations, clinic visits, day-care procedures), (3) clinical support services (operating theatres, pharmacy/consumables billed to patients, and other in-hospital service charges), and (4) diagnostics and allied services delivered either within hospital premises or through associated diagnostic operations. Payments are received from a mix of self-pay patients and institutional payers such as corporate arrangements, government/PSU programs, and private health insurers/TPAs, with reimbursement rates and package pricing influencing realized revenue per case. The company’s earnings are also affected by factors such as occupancy, case mix (complexity and specialty mix), average revenue per occupied bed (ARPOB), length of stay, pricing, and clinician availability; it may also enter into clinician engagement arrangements and third-party service contracts to expand specialty coverage and throughput. Specific partnership details are null.

Fortis Healthcare Ltd. Financial Statement Overview

Summary

Fortis Healthcare Ltd. shows strong financial performance with consistent revenue growth and improved profitability. The income statement is robust, with a high gross profit margin and positive net profit margins. The balance sheet is stable with a healthy equity ratio and improving debt-to-equity ratio. Cash flow management is effective, although fluctuations in capital expenditures warrant attention.

Income Statement

Fortis Healthcare Ltd. has demonstrated a strong income statement performance with consistent revenue growth, particularly from 2021 to 2025. The gross profit margin has remained robust, averaging above 40% in recent years, indicating effective cost management. Net profit margins have improved significantly, turning from negative to positive, showcasing enhanced profitability. EBIT and EBITDA margins have also seen notable improvements, indicating operational efficiency gains.

Balance Sheet

The company's balance sheet is solid with a healthy equity ratio, reflecting financial stability. The debt-to-equity ratio has been improving, suggesting prudent financial management and reduced leverage risk. Return on equity has increased, highlighting better efficiency in generating profits from shareholders' equity. However, the total debt level remains a consideration, though manageable given the company's growth trajectory.

Cash Flow

Fortis Healthcare Ltd. exhibits a positive cash flow trajectory, with significant growth in free cash flow over the years. The operating cash flow to net income ratio indicates strong cash-generating ability relative to accounting profits. However, fluctuations in capital expenditures and investing cash flows highlight potential volatility in future cash flows. Overall, cash flow management appears effective, supporting the company's expansion and operational needs.

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	84.34B	77.86B	68.97B	62.98B	57.18B	40.30B
Gross Profit	36.84B	45.86B	39.73B	23.08B	32.25B	20.72B
EBITDA	18.18B	15.00B	11.87B	10.37B	9.96B	3.47B
Net Income	10.14B	7.74B	5.99B	5.89B	5.55B	-1.10B
Balance Sheet
Total Assets	150.13B	136.92B	132.89B	124.34B	118.85B	111.55B
Cash, Cash Equivalents and Short-Term Investments	4.48B	5.08B	6.00B	3.66B	4.13B	4.16B
Total Debt	31.95B	24.75B	11.55B	9.26B	12.55B	15.31B
Total Liabilities	53.20B	45.22B	47.33B	43.33B	48.76B	44.37B
Stockholders Equity	94.29B	89.17B	76.63B	72.42B	61.78B	61.20B
Cash Flow
Free Cash Flow	800.30M	5.77B	1.58B	3.75B	6.50B	2.67B
Operating Cash Flow	6.76B	14.24B	11.00B	8.22B	8.65B	4.85B
Investing Cash Flow	-9.86B	-7.79B	-8.86B	-3.74B	-5.14B	-1.35B
Financing Cash Flow	2.46B	-7.14B	-864.58M	-4.71B	-5.17B	-1.43B

Fortis Healthcare Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 914.95
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:FORTIS, the sentiment is Negative. The current price of 914.95 is above the 20-day moving average (MA) of 902.26, above the 50-day MA of 891.45, and above the 200-day MA of 897.43, indicating a bearish trend. The MACD of -13.33 indicates Positive momentum. The RSI at 28.35 is Positive, neither overbought nor oversold. The STOCH value of 4.43 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:FORTIS.

Fortis Healthcare Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NH	71 Outperform	₹335.35B	75.82	―	0.24%	14.72%	8.37%
APOLLOHOSP	66 Neutral	₹1.08T	50.39	―	0.27%	13.66%	41.32%
LALPATHLAB	66 Neutral	₹224.60B	68.44	―	0.89%	10.80%	32.79%
FORTIS	61 Neutral	₹610.50B	86.12	―	0.11%	15.33%	54.62%
METROPOLIS	61 Neutral	₹95.39B	60.35	―	0.21%	15.41%	5.93%
MANKIND	59 Neutral	₹863.55B	55.46	―	0.04%	23.22%	-19.19%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Fortis Healthcare Ltd. Corporate Events

Fortis Healthcare Reports No Requests Under SEBI Physical Share Transfer Window

Fortis Healthcare has informed the stock exchanges about the status of a special window for re-lodgement of transfer requests for physical shares, as mandated by recent SEBI circulars. The company disclosed a report from its Registrar and Share Transfer Agent, KFin Technologies, confirming that no shareholder requests for re-lodgement of physical share transfers were received, processed, approved, or rejected during the specified period, indicating minimal impact on its share transfer operations under this regulatory window.

This disclosure underscores Fortis Healthcare’s compliance with SEBI’s regulatory framework on physical share transfers and provides transparency to investors and regulators on the usage of the special re-lodgement facility. The absence of activity in this window suggests that most shareholders may have already transitioned to dematerialised holdings, reducing operational risk and aligning the company’s shareholder base with broader market moves toward electronic securities.

Fortis Healthcare Completes Merger of Key Subsidiaries into Fortis Hospitals

Fortis Healthcare has announced that its composite scheme of merger by absorption involving several wholly owned subsidiaries has become effective following regulatory filings. The company filed certified orders from the National Company Law Tribunal’s Delhi and Chandigarh benches with the Registrar of Companies on March 1, 2026, bringing the scheme into force.

Under the scheme, Fortis Emergency Services Limited, Fortis Cancer Care Limited, Fortis Health Management (East) Limited, and Birdie & Birdie Realtors Private Limited have been merged into Fortis Hospitals Limited. The consolidation is expected to streamline the group’s corporate structure and internal operations by integrating these businesses under a single hospital-focused entity.

Fortis Healthcare Plans U.S. Investor Roadshow and Conference Meetings in January 2026

Fortis Healthcare has announced a series of in-person investor and analyst meetings in the United States in January 2026, including a non-deal roadshow in New York and Boston organized by J.P. Morgan and participation in the J.P. Morgan 2026 Healthcare Conference in San Francisco. The sessions, which will feature one-on-one and group meetings focused on general business and industry updates, underscore the company’s efforts to deepen engagement with global investors, enhance transparency, and potentially strengthen its visibility and positioning within the international healthcare investment community, while confirming that no unpublished price-sensitive information will be shared and related presentations will be publicly disclosed in advance.

Fortis Healthcare Plans Global Investor Outreach at J.P. Morgan Events

Fortis Healthcare has announced a series of upcoming investor and analyst interactions, including an in-person non-deal roadshow organized by J.P. Morgan in New York and Boston on January 12–13, 2026, and participation in the J.P. Morgan 2026 Healthcare Conference in San Francisco on January 15, 2026. These one-on-one and group meetings, aimed at providing a general business and industry update without sharing unpublished price-sensitive information, underscore the company’s efforts to deepen engagement with global investors and analysts, potentially enhancing its visibility and positioning in international capital markets.

Fortis Healthcare Schedules U.S. Investor Meetings and J.P. Morgan Conference Participation

Fortis Healthcare Limited has announced a schedule of upcoming investor and analyst interactions in the United States, including a non-deal roadshow organized by J.P. Morgan in New York and Boston on January 12–13, 2026, and participation in the J.P. Morgan 2026 Healthcare Conference in San Francisco on January 15, 2026. The meetings, to be held in person through one-on-one and group formats, are intended to provide a general business and industry update, with the company emphasizing that no unpublished price-sensitive information will be shared and that the related investor presentation will be disclosed to stock exchanges in advance, underscoring its focus on regulatory compliance and transparent engagement with global investors.

Fortis to Acquire TMI Healthcare, Expanding Hospital Network in Bengaluru

Fortis Healthcare’s wholly owned subsidiary, International Hospital Limited, has signed definitive agreements to acquire TMI Healthcare Private Limited, which primarily comprises hospital operations, along with the underlying hospital land, building and an adjacent land parcel in Bengaluru. The deal, which centers on the People Tree Hospital in Yeshwanthpur (with related facilities to be carved out before closing), aligns with Fortis’s cluster-focused growth strategy and is intended to further consolidate its network and competitive position in the Bengaluru healthcare market, though completion remains subject to customary conditions precedent and closing conditions.

Fortis to Invest About INR 840 Crore to Expand Bengaluru Hospital Capacity

Fortis Healthcare has signed definitive agreements to acquire the 125-bed People Tree Hospital in Yeshwanthpur, Bengaluru, through its wholly owned subsidiary International Hospital Limited by purchasing 100% of TMI Healthcare Private Limited and related real estate assets for a cumulative transaction value of INR 430 crore, including debt. The deal, which is expected to close by the end of January 2026, includes the acquisition of an adjacent 0.8-acre land parcel that will allow Fortis to expand the facility to more than 300 beds, supported by an additional planned investment of about INR 410 crore over the next three years in infrastructure, medical equipment and clinical programs such as radiation oncology; this move strengthens Fortis’s cluster-based expansion strategy in Bengaluru, enhancing its presence from the current 900 beds toward a potential 1,500-plus beds across seven facilities and positioning the company to grow revenues and profitability from the hospital’s existing business base.